A statewide coalition led by NCBiotech has received a Phase 2 award totaling nearly $25 million from the U.S. EDA's Build Back Better Regional Challenge.

The artificial intelligence revolution has come to North Carolina’s life sciences sector in a big way, as companies from the smallest startups to global drug manufacturers deploy AI across almost all functions.

For patients with rare diseases, finding a relevant clinical trial can be a difficult and fragmented process, but a new partnership is creating a more connected pathway for patients and providers.

North Carolina is in an unprecedented period of reinvestment for its biomanufacturing workforce training. Community colleges across the state have been making investments exceeding $230 million over the past few years. This commitment to new and expanded life sciences training programs and facilities builds on the state's history and strength in workforce development.

It has been known for years by insiders as the “hidden gem” of North Carolina’s life sciences ecosystem. And now, after four decades of unique and valuable service to partners statewide, the North Carolina Biotechnology Center’s (NCBiotech’s) Life Sciences Intelligence (LSI) unit is now a “gem on display.” 

NCBioImpact, a public/private partnership created to bring together key resources to produce world-class biopharma manufacturing training programs, organized a unique event to enhance communication and information-sharing around workforce training and development.

North Carolina’s reputation as a leading state for life sciences is well-known, both in the United States and globally.

But there’s no guarantee that will always be the case. Pharmaceutical and biotechnology leaders, working in conjunction with others who are a part of the state’s life sciences ecosystem, can’t sit still while the rest of the world catches up, speakers at a recent conference in Raleigh emphasized.